#USA #New York #Securities Fraud #Pomerantz #PetMed

Pomerantz Law Firm Investigates PetMed Express, Inc.

The Pomerantz Law Firm has initiated an investigation into PetMed Express, Inc. (NASDAQ: PETS) regarding potential claims from investors. The focus of this investigation is to explore whether the company, along with certain officers and directors, engaged in securities fraud or other unlawful business practices. This alarming inquiry follows a series of concerning announcements regarding the company’s financial disclosures and abnormal stock price fluctuations.

Background on PetMed's Recent Press Releases

On June 10, 2025, PetMed communicated a significant delay in its fourth-quarter and fiscal year 2025 earnings release. The company stated it needed more time to wrap up the year-end audit process. This announcement adversely affected the stock market, resulting in a plunge in PetMed's share price by 11.22%, equating to a drop of $0.47, closing at $3.72 per share on June 11, 2025.

Later, on July 1, 2025, the company further compounded its troubles by announcing a delay in the filing of its Annual Report for fiscal year 2025. This was triggered, in part, due to an internal investigation concerning revenue recognition issues. Again, the market reacted negatively, and PetMed’s share price fell by 1.51%, closing the day at $3.27 per share.

The situation escalated when, on November 12, 2025, PetMed revealed it was incapable of filing its third-quarter report for 2025 on time due to difficulties in completing its financial reporting. This delay was attributed to the completion of a previously disclosed investigation by the company's Audit Committee. As a direct consequence, the company saw its stock price plummet to $1.96 per share by November 13, 2025—a staggering 32.41% decline, or a drop of $0.94 per share.

The Role of Pomerantz Law Firm

Pomerantz LLP, well-regarded for its expertise in corporate and securities litigation, has initiated this inquiry with the aim of protecting the interests of affected investors. The firm was founded by Abraham L. Pomerantz, who played a pivotal role in developing the field of securities class actions. For over 80 years, Pomerantz has been a leader in advocating for the victims of securities fraud and corporate misconduct. This latest investigation reflects its ongoing commitment to holding companies accountable for their actions.

Investors affected by PetMed's recent financial disclosures are encouraged to contact Danielle Peyton at Pomerantz LLP for further details regarding their legal rights and potential claims.

Conclusion

As this situation unfolds, affected investors and market watchers will be keenly observing the developments stemming from the investigation led by Pomerantz LLP. With monetary losses already evident, the implications of the findings could affect not only PetMed Express, Inc. but also highlight broader issues surrounding corporate governance and securities regulations in the market today. Investors should remain vigilant and seek updates on these proceedings for their financial interests and rights.

For any queries or to join the ongoing class-action inquiries, interested parties should reach out directly to Pomerantz LLP. It remains critical for investors to stay informed and prepared for further developments in the PetMed case.